Share
Share today's newsletter with a colleague
and get credit if they sign up for SmartBrief.
Referral Count:
0
Story being shared
Salix's AIDS/HIV-related diarrhea drug Fulyzaq gets FDA nod
Salix Pharmaceuticals' Fulyzaq, or crofelemer, has been approved by the FDA to treat diarrhea in HIV/AIDS patients undergoing antiretroviral therapy.
This makes Fulyzaq, developed by Napo Pharmaceuticals, the first approved treatment for HIV/AIDS patients whose diarrhea is not caused by bacteria, virus or parasite.
Or we can send an email on your behalf